Top Markets
#1 EXOD EXOD +56.80%
#2 CoW Protocol CoW Protocol +52.24%
#3 Glidr Glidr +36.41%
#4 Walrus Walrus +29.81%
#5 Cysic Cysic +20.00%
#6 The Black Bull The Black Bull +18.44%
#7 Humanity Humanity +15.87%
#8 Fabric Protocol Fabric Protocol +14.98%
#9 Nockchain Nockchain +14.31%
#10 Tutorial Tutorial +13.13%
Coin of the day
EXOD EXOD
Settings
Language
ENGLISH
Currency
USD
Theme
Restart Life Sciences Corp. Restart Life Sciences Corp.

Restart Life Sciences Corp.

HEAL
Rank in Stocks #37250
Operating internationally through its various subsidiaries, Restart Life... Operating internationally through its various subsidiaries, Restart Life Sciences Corp. functions as a biotechnology firm. Its core endeavors include the creation of natural therapeutic remedies tailored for individuals with autism spectrum disorder, the development of health-promoting foods designed for comprehensive mind and body wellness, and the execution of a psilocybin clinical trial aimed at fragile X syndrome. Founded in 2004 and based in Vancouver, Canada, the company adopted its current name in November 2024, having previously been known as Nova Mentis Life Science Corp.
Share Price
$0.05137558
Last synced: 2026-08-13
Market Cap
$1.88M
Change (1 day)
0.00%
Change (1 year)
-11.66%
Country
CA
Trade Restart Life Sciences Corp. (HEAL)

Category

Healthcare
P/E ratio for Restart Life Sciences Corp. (HEAL)
P/E ratio as of 2026 TTM: 0
According to Restart Life Sciences Corp. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Restart Life Sciences Corp. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 18.38 -
BE
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.